U.S. Markets closed

IMV Inc. (IMV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6752+0.0208 (+3.18%)
At close: 04:00PM EDT
0.6900 +0.01 (+2.19%)
After hours: 06:12PM EDT

IMV Inc.

130 Eileen Stubbs Avenue
Suite 19
Dartmouth, NS B3B 2C4

Full Time Employees97

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew Hall M.Sc.CEO & Director273.71kN/AN/A
Ms. Brittany Davison C.A., CPAVP of Fin.N/AN/AN/A
Dr. Jeremy R. GraffChief Scientific OfficerN/AN/AN/A
Ms. Joy Bessenger B.A.Sr. VP of Investor Relations & Corp. StrategyN/AN/AN/A
Ms. Annie Tanguay B.Sc.Sr. VP of Quality & ComplianceN/AN/AN/A
Delphine DavanSr. Director of Communications & Investor RelationsN/AN/AN/A
Ms. Linda Barabe M.B.A.VP of HRN/AN/AN/A
Dr. Marianne StanfordVP of R&DN/AN/AN/A
Mr. Stephan FisetVP of Clinical ResearchN/AN/AN/A
Dr. Heather HirschVP of Translational ResearchN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Corporate Governance

IMV Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 7; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.